ホーム › 乳がん › カリフォルニア州 › San Diego
San Diego、CAにおける乳がんの臨床試験
San Diegoとその周辺地域（約30マイル以内）の拠点で、乳がんに関する41件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
被験者募集中第3相
- University of California San Diego Moores Cancer Center, San Diego
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- University of San Diego Moores Cancer Center, La Jolla · 11マイル先
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
被験者募集中第3相
- Sharp Rees Stealy Medical Group Inc, San Diego
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
被験者募集中第1相
- University of California San Diego Moores Cancer Center, San Diego
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
被験者募集中第1/2相
- Sharp Memorial Hospital, San Diego
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
被験者募集中第2相
- California Protons Cancer Therapy Center, San Diego
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
被験者募集中第3相
- California Protons Cancer Therapy Center, San Diego
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
被験者募集中第2相
- UC San Diego Moores Cancer Center, La Jolla · 11マイル先
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
被験者募集中第3相
- Clinical Trial Site, La Jolla · 11マイル先
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
被験者募集中第3相
- Moores Cancer Center, La Jolla · 11マイル先
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
被験者募集中健康なボランティア歓迎
- University of California San Diego, San Diego
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
被験者募集中第3相
- University Of California - San Diego Moores Cancer Center, La Jolla · 11マイル先
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
被験者募集中第3相
- UC San Diego Moores Cancer Center, La Jolla · 11マイル先
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
被験者募集中第1/2相
- University of California San Diego (UCSD) - Koman Family Outpatient Pavilion ? La Jolla, La Jolla · 11マイル先
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
被験者募集中第1相
- Scripps Health, San Diego
A Phase 1/1b Study of IAM1363 in HER2 Cancers
被験者募集中第1相
- UCSD Moores Cancer Center, La Jolla · 11マイル先
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
被験者募集中第1/2相
- University of California San Diego Medical Center, San Diego
- UC San Diego Moores Cancer Center, La Jolla · 11マイル先
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
被験者募集中第1相
- University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla · 11マイル先
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
被験者募集中第1/2相
- University of California-San Diego, La Jolla · 11マイル先
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
被験者募集中第3相
- Scripps Health, La Jolla · 11マイル先
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
被験者募集中第3相
- UC San Diego, San Diego
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
被験者募集中第1相
- UC San Diego Moores Cancer Center, La Jolla · 11マイル先
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
被験者募集中観察研究
- University of California, San Diego, San Diego
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
被験者募集中第3相
- Kaiser Permanente-Rio San Diego, San Diego
- Kaiser Permanente-San Diego Zion, San Diego
A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer
被験者募集中健康なボランティア歓迎
- University of California, San Diego, La Jolla · 11マイル先
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
被験者募集中第1相
- UC San Diego Moores Cancer Center, La Jolla · 11マイル先
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
被験者募集中第2相
- Scripps Health, San Diego
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
被験者募集中第3相
- UC San Diego Medical Center - Hillcrest, San Diego
- California Protons Cancer Therapy Center, San Diego
- UC San Diego Moores Cancer Center, La Jolla · 11マイル先
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
被験者募集中第1相
- University of California, San Diego, La Jolla · 11マイル先
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
被験者募集中第3相
- University of California San Diego - Moores Cancer Center, La Jolla · 11マイル先
E-Mindfulness Approaches for Living After Breast Cancer
被験者募集中第3相
- Kaiser Permanente-San Diego Zion, San Diego
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
被験者募集中第1/2相
- University of California, San Diego; Moores Cancer Center, San Diego
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Investigative Site #101, La Jolla · 11マイル先
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
被験者募集中第2相
- University of California San Diego, La Jolla · 11マイル先
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
被験者募集中第1/2相
- SHARP Healthcare, San Diego
Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.
被験者募集中第2相
- University of California, San Diego, La Jolla · 11マイル先
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
被験者募集中第1/2相
- Research Site, La Jolla · 11マイル先
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
被験者募集中
- UC San Diego Health, La Jolla · 11マイル先
Efficacy of OneMark Device in Identifying Breast Cancer for Surgery and Surveillance
被験者募集中
- University of California, San Diego, La Jolla · 11マイル先
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, La Jolla · 11マイル先
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
被験者募集中第1相
- University of California-San Diego, San Diego
他の都市における乳がんの試験
- New York City, NY136件の研究
- Houston, TX126件の研究
- Boston, MA112件の研究
- Nashville, TN81件の研究
- Los Angeles, CA73件の研究
- Edison, NJ68件の研究
- St. Louis, MO64件の研究
- Queens, NY64件の研究
- Durham, NC64件の研究
- Chicago, IL59件の研究
- Philadelphia, PA56件の研究
- Dallas, TX55件の研究
San Diegoにおける他の研究
- 非小細胞肺癌48件の研究
- がん（全種類）32件の研究
- 前立腺がん31件の研究
- 転移性癌30件の研究
- 大腸癌25件の研究
- 卵巣がん24件の研究
- 膵臓がん24件の研究
- 肺がん23件の研究
- 肥満症23件の研究
- 心不全23件の研究
- うつ病21件の研究
- 悪性黒色腫18件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。